CAMBRIDGE, Mass., June 16, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced key new hires in the medical affairs and drug safety functions.
Chief Executive Officer Marc D. Beer commented, "As our business grows in scope and complexity globally with two products, we are continuing to add depth and expertise across the organization to support this global growth, and to expand Aegerion's leadership breadth, particularly in areas that play a key role in important clinical initiatives."
Jerome Premmereur, MD, joins Aegerion as Vice President, Global Head of Medical Affairs. Dr. Premmereur was previously senior safety leader at Novartis Vaccines. He has more than 20 years of experience in pharmaceutical development, the last 10 of which were dedicated to global medical affairs including in the areas of thrombosis, cardiology, metabolism and oncology.
Sam Yonren, MD, joins Aegerion as Vice President, Global Head of Drug Safety. Dr. Yonren previously led global pharmacovigilance at Seattle Genetics. He has managed product safety with regulators in North America, Europe and Japan, while overseeing post-marketing activities in various therapeutic areas.
Chief Medical Officer, Mark Sumeray, MD, MS, FRCP, commented, "With clinical development continuing under the leadership of Dr. Pamela Foulds, we have established a strong foundation in drug development. We look forward to the contributions of Sam and Jerome in our efforts."
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.